Business Context and Reporting Period
Company: Agios Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 12, 2026
Reporting Period: Quarter and year ended December 31, 2025
This filing serves as a notification that the company issued a press release on February 12, 2026, announcing its financial results for the fourth quarter and full year of 2025. The detailed financial data is contained in Exhibit 99.1 (the press release), which is furnished but not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Financial Metrics
The provided text for this Form 8-K does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the press release (Exhibit 99.1) but are not present in the filing text itself.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only confirms that results for the quarter and year ended December 31, 2025, were announced.
Guidance, Outlook, and Risks
The filing text does not include specific guidance, outlook, management commentary, risks, contingencies, or unusual items. It references "other business highlights" in the press release but does not enumerate them.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for Q4 and FY 2025.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the "business highlights."
- Confirm if the press release contains updated financial guidance for 2026.